Our mission at LungLife is driven from important and compelling statistical data about lung cancer. According to the American Society of Clinical Oncology, Lung cancer is the leading cancer killer in the world. At LungLife, we’re creating a different future.
While lung cancer isn’t totally preventable, early detection is key to a positive prognosis. Data published on the Centers for Disease Control and Prevention website says that cigarette smoking is responsible for 80-90% of all lung cancer diagnoses. Other causes include chemicals like radon, second-hand smoke, air pollution, and possible genetic factors. With cigarette smoking being such a dominant correlative factor in the diagnosis of lung cancer, current and former smokers must be diligent in following their doctors’ recommendations when it comes to timely screenings. Others at risk should also keep current with screening guidance.
The current tool for lung cancer screening consists of a low-dose computed tomography (low-dose CT scan). When a mass is found, the patient either submits to an invasive biopsy or is told to wait for a period of time before returning for another CT scan to see if the mass has grown (and potentially spread). Both options can be quite stressful for the patient and support circle.
Here’s where we have some exciting news to share. Our company is using artificial intelligence to aid with the early detection of lung cancer. LungLife has developed technology that pairs a simple blood draw with artificial intelligence to provide clinicians and patients the information they need to make informed decisions about the management of lung nodules and lung cancer. Early detection means better care, better outcomes, and longer lives.
We at LungLife strive to be a driving force in the early detection of lung cancer.
For more information about the great work we are doing, visit our website at lunglife.ai.com.